TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02924090

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etomidate
Description: Etomidate will be administered as a bolus intravenously to induce an adequate depth of anesthesia just prior to ECT at a dose of 0.3 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etomidate
Description: Etomidate will be administered as a bolus intravenously to induce an adequate depth of anesthesia just prior to ECT at a dose of 0.3 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine will be administered as a bolus intravenously to induce an adequate depth of anesthesia just prior to ECT at a dose of 0.5 to 1.0 mg/kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine will be administered as a bolus intravenously to induce an adequate depth of anesthesia just prior to ECT at a dose of 0.5 to 1.0 mg/kg.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperventilation
Description: Hyperventilation will be performed in patients after full pre-oxygenation and induction of anesthesia, by administering 20 breaths in 30 seconds using a well-fitting face mask immediately before application of the ECT electrical stimulus.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperventilation
Description: Hyperventilation will be performed in patients after full pre-oxygenation and induction of anesthesia, by administering 20 breaths in 30 seconds using a well-fitting face mask immediately before application of the ECT electrical stimulus.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electroconvulsive therapy (ECT)
Description: Bilateral, bitemporal electrode placement will be utilized to elicit a seizure via a SpECTrun 5000Q (MECTA Inc.). The electrical dose required will be determined in advance by the patient's attending psychiatrist.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electroconvulsive therapy (ECT)
Description: Bilateral, bitemporal electrode placement will be utilized to elicit a seizure via a SpECTrun 5000Q (MECTA Inc.). The electrical dose required will be determined in advance by the patient's attending psychiatrist.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electroconvulsive therapy (ECT)
Description: Bilateral, bitemporal electrode placement will be utilized to elicit a seizure via a SpECTrun 5000Q (MECTA Inc.). The electrical dose required will be determined in advance by the patient's attending psychiatrist.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electroconvulsive therapy (ECT)
Description: Bilateral, bitemporal electrode placement will be utilized to elicit a seizure via a SpECTrun 5000Q (MECTA Inc.). The electrical dose required will be determined in advance by the patient's attending psychiatrist.
Study: NCT03072524

Intervention type: DIAGNOSTIC_TEST
Intervention: FAST PLUS test
Description: FAST PLUS test consists of two parts: the first one is the standard FAST test, which evaluates Speech (0-1), Facial palsy (0-1), Arm motor function (0-1), Time (0-1). The second part of the FAST PLUS test evaluates only the presence of severe arm or leg motor deficit (0-1), and unilateral occurrence of this motor function deficit (0-1).
Study: NCT00604708

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IC51
Description: IC51 (JE-PIV), 6 mcg, i.m. injection, 2 vaccinations, days 0 and 28

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: JE-VAX
Description: JE-VAX, 1mL s.c. injection, 3 vaccinations, days 0, 7 and 28
Study: NCT03648359

Intervention type: PROCEDURE
Group type: OTHER
Intervention: multiparametric MRI Diagnostics
Description: Patients with newly diagnosed prostate cancer enrolled in active surveillance following standard protocol including PSA, DRE and TRUS biopsies and intervention with multiparametric MRI + additional biopsies if suspicious lesions are found
Study: NCT00267514

Intervention type: DRUG
Group type: OTHER
Intervention: sevelamer carbonate (Renvela®) sevelamer hydrochloride (Renagel ®)
Description: sevelamer carbonate powder dosed TID with meals for four weeks followed by sevelamer hydrochloride tablets dosed TID with meals for four weeks

Intervention type: DRUG
Group type: OTHER
Intervention: sevelamer hydrochloride (Renagel ®) sevelamer carbonate (Renvela®)
Description: sevelamer hydrochloride tablets dosed TID with meals for four weeks followed by sevelamer carbonate powder dosed TID with meals for four weeks
Study: NCT03846440

Intervention type: OTHER
Intervention: No intervention
Description: Cross-sectional
Study: NCT00499967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9191 ointment
Description: GS-9191 ointment (0.01%, 0.03%, or 0.1%) or placebo applied topically to anogenital warts for one or three cycles, each cycle lasting 5 consecutive nights of ointment application followed by 9 nights off-ointment. The strength of GS-9191 ointment is cohort-dependent, with escalation to higher dose cohorts dependent upon safety and tolerability in the previous cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9191 ointment
Description: GS-9191 ointment (0.01%, 0.03%, or 0.1%) or placebo applied topically to anogenital warts for one or three cycles, each cycle lasting 5 consecutive nights of ointment application followed by 9 nights off-ointment. The strength of GS-9191 ointment is cohort-dependent, with escalation to higher dose cohorts dependent upon safety and tolerability in the previous cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9191 ointment
Description: GS-9191 ointment (0.01%, 0.03%, or 0.1%) or placebo applied topically to anogenital warts for one or three cycles, each cycle lasting 5 consecutive nights of ointment application followed by 9 nights off-ointment. The strength of GS-9191 ointment is cohort-dependent, with escalation to higher dose cohorts dependent upon safety and tolerability in the previous cohort.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS-9191
Description: GS-9191 ointment (0.3% or 1.0%) or placebo applied topically to anogenital warts for one or three cycles; each cycle consists of dosing occuring over a 5-night period with ointment application on nights 1, 3 and 5 followed by a 9-day off-ointment period. The strength of GS-9191 ointment is cohort-dependent, with escalation to higher dose cohorts dependent upon safety and tolerability in the previous cohort.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS-9191
Description: GS-9191 ointment (0.3% or 1.0%) or placebo applied topically to anogenital warts for one or three cycles; each cycle consists of dosing occuring over a 5-night period with ointment application on nights 1, 3 and 5 followed by a 9-day off-ointment period. The strength of GS-9191 ointment is cohort-dependent, with escalation to higher dose cohorts dependent upon safety and tolerability in the previous cohort.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching GS-9191 ointment
Study: NCT03570723

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: A glove-loaded Foley's catheter tamponade
Description: A glove-loaded Foley's catheter tamponade, the internal os of the cervix was identified and a double-way 20 Fr Foley's catheter with a 30-50-ml balloon was inserted through the cervix to be handled by an assistant through the vagina and fixed to the patient's lower limb after inflation of the catheter balloon by 300 ml warm saline and pulling it against the lower uterine segment between the two transverse sutures. Only one glove-loaded Foley's catheter was used for tamponade.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stepwise uterine devascularization
Description: Uterine hemostatic sutures, through examination of the placental bed, may use some hemostasis at the placental bed,overswing was commenced using endo-uterine sutures. If there is still significant bleeding, bilateral uterine artery ligation, and internal iliac artery ligation when needed.BUAL started immediately through blunt dissection downwards and laterally of the peritoneum covering the uterine isthmus and cervix. The peritoneum is mobilized freely at the uterine angles to expose both uterine arteries and avoid inclusion of the ureters in the ligation. The uterine artery pulsations were palpated digitally at the level of the internal os.
Study: NCT02984007

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Mothers randomized in the intervention group will receive an educational session based on the motivational interviewing (MI) approach with a research assistant (RA). The RA will have first received a standardized training session on the content and techniques of MI.~The MI intervention will be carried out in simple and understandable language in order to allow discussion and questions from parents rather than provide prescriptive and direct information. The intervention will last approximatively 15 to 20 minutes.
Study: NCT00833404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine transdermal patch
Description: 8-week nicotine patch regimen (21mg/day during week 1-4, 14mg/day during week 5-6, and 7mg/day during week 7-8).
Study: NCT04325867

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-medicine platform
Description: Electronic counselling of known pathology cardiovascular patients through a complex remote platform and dedicated experts. This project intend remote monitoring through wearable devices (e.g. ECG watches, pulse detectors, oximetry).
Study: NCT00784589

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General Corticotherapy
Description: for patients with severe pemphigus : general corticotherapy Arm : 1.5mg/kg/d for 1 month, then 1.25mg/kg/d for 1 month, then 1mg/kg/d for 1 month, then 0.75 mg/kg/d for 1 month, then 0.5 mg/kg/d for 3 months, then 0.3 mg/kg/d for 3 months, then 0.2 mg/kg/d for 4 months, then 0.1 mg/kg/d for 4 months, for patients with moderated pemphigus : general corticotherapy Arm : 1mg/kg/d for 1 month, then 0.75mg/kg/d for 1 month, then 0.5mg/kg/d for 2 months, then 0.3 mg/kg/d for 2 months, then 0.2 mg/kg/d for 3 months, then 0.1 mg/kg/d for 3 months,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: for patients with severe pemphigus : rituximab Arm : 1mg/kg/d for 1 month, then 0.75 mg/kg/d for 1 month, then 0.5 mg/kg/d for 1 month, then 0.3 mg/kg/d for 1 month, then 0.2 mg/kg/d for 1 month, then 0.1 mg/kg/d for 1 month for patients with moderated pemphigus : rituximab Arm : 0.5mg/kg/d for 1 month, then 0.30 mg/kg/d for 1 month, then 0.2 mg/kg/d for 1 month,
Study: NCT05034380

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acute exercise
Description: All participants consumed a standardized, high carbohydrate meal (7 kcal/kg; 60% carbohydrate, 25% fat, 15% protein) and completed an exercise testing trial, expending a total of 650 kcal upon completion 4h later.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acute exercise
Description: All participants consumed a standardized, high carbohydrate meal (7 kcal/kg; 60% carbohydrate, 25% fat, 15% protein) and completed an exercise testing trial, expending a total of 650 kcal upon completion 4h later.
Study: NCT01737879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginesatide
Description: All participants will receive peginesatide for the first 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Description: All participants converted to epoetin alfa at week 25 for a total of 32 weeks
Study: NCT03368118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX464
Description: All subjects will receive ABX464 given at 50 mg o.d for an overall period of 48 months.
Study: NCT00159952

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intensive insulin therapy
Description: control: glycemia will be controlled with insulin administration when higher than 215 mg/dL.~treatment: glycemia will be controlled with be controlled with insulin administration when higher than 110 mg/dL
Study: NCT02540122

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Marketed Contact Lens 1
Description: Marketed contact lens being worn by the subject in a bilateral fashion for approximately 6 hours (+/- 30 minutes).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Marketed Contact Lens 1
Description: Marketed contact lens being worn by the subject in a bilateral fashion for approximately 6 hours (+/- 30 minutes).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Marketed Contact Lens 2
Description: Marketed contact lens being worn by the subject in a bilateral fashion for approximately 6 hours (+/- 30 minutes).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Marketed Contact Lens 2
Description: Marketed contact lens being worn by the subject in a bilateral fashion for approximately 6 hours (+/- 30 minutes).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Marketed Contact Lens 3
Description: Marketed contact lens being worn by the subject in a bilateral fashion for approximately 6 hours (+/- 30 minutes).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Marketed Contact Lens 3
Description: Marketed contact lens being worn by the subject in a bilateral fashion for approximately 6 hours (+/- 30 minutes).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Marketed Contact Lens 4
Description: Marketed contact lens being worn by the subject in a bilateral fashion for approximately 6 hours (+/- 30 minutes).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Marketed Contact Lens 4
Description: Marketed contact lens being worn by the subject in a bilateral fashion for approximately 6 hours (+/- 30 minutes).
Study: NCT02739659

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: carbon-ion radiotherapy
Study: NCT01888952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Patients may receive additional courses of treatment with prednisone (and roflumilast) at the discretion of the investigator if they did not experience unacceptable toxicity and have stable disease or objectively responding disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: Patients may receive additional courses of treatment with roflumilast (and prednisone) at the discretion of the investigator if they did not experience unacceptable toxicity, and have stable disease or objectively responding disease.
Study: NCT02253888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPV - Room condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPV - Refrigerated conditions
Study: NCT02984007

Intervention type: OTHER
Group type: OTHER
Intervention: Information flyer
Description: Mothers randomized in the control group will receive a locally information flyer on childhood vaccines without any oral explanation by the research assistant.
Study: NCT02395731

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MIND at Home-Plus Intervention
Description: MIND at Home-Plus is a home-based, care coordination that focuses on persons with dementia living at home and their family caregivers. Its goal is to help persons age in place safely while increasing quality of life. Delivered over 18 months, MIND-Plus systematically assesses and addresses unmet care needs of persons with dementia and their caregivers which are known to be linked to poor health and quality of life outcomes, and that put people at risk for long term care placement. The needs addressed in the MIND program cover a wide range of care domains, ranging from home and medication safety, to cognitive and behavior symptoms management, meaningful activities and legal considerations. The care team made up of a memory care coordinator, nurse, occupational therapist, and physician.
Study: NCT02169570

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vit D

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Calcium

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Calcium
Study: NCT03905343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib 600mg p.o. d1-21, q4w in combination with endocrine treatment for 3 years.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mono-chemotherapy
Description: mono-chemotherapy for at least 12 weeks (afterwards, maintenance endocrine therapy ± ribociclib inhibitor is allowed) and up to 3 years.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endocrine-Therapy
Description: The choice of endocrine therapy is up to the investigator, but the chosen endocrine therapy has to be registered to be used in combination with ribociclib in the investigated indication.
Study: NCT00304759

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 7800 cGy/39 fractions in 8 weeks
Description: see above

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 6000 cGy/20 fractions in 4 weeks
Description: see above
Study: NCT03560024

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PACAP27
Description: PACAP27 is vasodilator of cerebral vessels

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study: NCT02546297

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort
Description: drug are used for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort
Description: drug are used for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spiriva
Description: drug are used for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spiriva
Description: drug are used for 12 months
Study: NCT00658905

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhBSSL
Description: 0.15 g/L rhBSSL added to infant formula; one week treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One week treatment
Study: NCT04419922

Intervention type: BEHAVIORAL
Intervention: Smartphone Contingency Management Intervention
Description: Participants will provide baseline data on their recent substance use and smoking habits/severity. Participants will 1) download the DynamiCare Rewards app, and 2) receive a Carbon Monoxide breath testing device (iCO™ Smokerlyzer®) and reloadable debit card for receiving financial incentives. Participants will follow instructions on the app to take breath tests and receive incentives if the carbon monoxide breath result is less than 6 ppm (Cessation mode) or lower than 3 of the last 4 tests (Shaping mode). The app will use GPS to track if patients have attended their scheduled BrightView appointments (GPS is not used at any other time) and reward them for all kept appointments. The participant will also be able to view Cognitive Behavioral Therapy (CBT) modules on the app and receive incentives upon completing each module. At all times, the participant retains the right to choose whether to use and when to use the app, device, and funds for a total period of 4 months.
Study: NCT01250509

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Craving and Lifestyle Management through Mindfulness
Description: A preliminary, novel intervention was developed drawing on components from Mindfulness-Based Stress Reduction (MBSR), Mindfulness-Based Cognitive Therapy (MBCT), and Mindfulness-Based Eating Awareness Training (MB-EAT). The intervention program consisted of nine 2.5-hour classes and one 7-hour silent day of guided meditation practice after class 6.
Study: NCT01843725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: escalation dose of capecitabine continuously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aflibercept
Description: Intravenous 6mg/kg every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aflibercept
Description: Intravenous 6mg/kg every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: dose escalation, from 1700 to 2500mg/m2/day 2 weeks out of 3
Study: NCT01070446

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin: Choline Bitartrate (2-hydroxyethyl) trimethylammonium salt 1:1
Description: This is a prospective, repeated measures study involving children with Cystic Fibrosis. Children will be assessed (1) before starting the choline supplement, (2) after taking the supplement for 6 months and after the supplement has been discontinued for 3 months.
Study: NCT02253888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir (RTV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir (RTV)
Study: NCT02736708

Intervention type: DEVICE
Intervention: probe based confocal laser endomicroscopy
Description: real-time, microscopic imaging of tissue at the cellular level via a small diameter probe.
Study: NCT00482170

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enbrel (etanercept)
Description: Arm 1 = Enbrel 50 mg Prefilled Syringe twice weekly

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: Arm 2 = Enbrel 50 mg Autoinjector twice weekly
Study: NCT00271219

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: daily oral dosing 20-140 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: sl daily 2-32 mg
Study: NCT02025270

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Stem Cells
Description: 60 ml of bone marrow will aspirated and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared using GMP rules and finally injected into rete testis.
Study: NCT01083992

Intervention type: DRUG
Group type: OTHER
Intervention: Galvus (vitagliptin)
Description: Galvus (vitagliptin)

Intervention type: DRUG
Group type: OTHER
Intervention: Galvus + vitamin D
Description: Galvus + vitamin D
Study: NCT04598308

Intervention type: DIAGNOSTIC_TEST
Intervention: absolute flow and resistance measurements
Description: This registry only collects all measurement data from normal/routine physiologic assessment in the cathlab. These measurements are performed on a daily basis~Short description of the procedure Coronary angiography, PCI (if indicated), and physiologic measurements are performed completely according to normal routine. Physiologic measurements may include FFR, NHPR, IMR, CFR, absolute flow (Q) and microcirculatory resistance (Rmicro or MRR) measurement.~Intention to measure Q and Rmicro are mandatory to be included in this registry.~Use of drugs either during or after the procedure should also exactly identical to normal routine.
Study: NCT01509001

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 750 to 2500 mg/day, two times a day during 4 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: 1 to 8 mg/day , two times a dya, during 4 months.